Promoting Recognition, Diagnosis and Treatment of Cold Agglutinin Disease

To participate in this activity, please:

Cold Agglutinin Disease is a rare, chronic hemolytic disorder, representing approximately 20% of all autoimmune hemolytic anemias. Catherine M. Broome, MD, and Alexander Röth, MD, provide an understanding of the pathogenesis of this disorder caused by cold-reacting IgM autoantibodies and reveal common clinical features. Because of the high mortality rate among those suffering from CAD, it is important to be aware of the diagnostic criteria, as well as the current and novel treatment options, with the goal of increasing hemoglobin levels, avoiding the need for transfusions, and improving circulatory symptoms. Dr. Broome discusses the most recent advancements in treatment based on global collaborative efforts and the importance of participating in the CADENCE Registry. Significant findings from the phase 3 CARDINAL trial are also presented along with an interactive case scenario.

This program is also available as a podcast.  You may download it here: https://anchor.fm/coldagglutinindisease

Course Credit:

1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour
0.75 Pharmacology Hours

Dates:

Opens: 2021-08-31
Closes: 2022-08-31

Target Audience:

This activity was developed for adult hematologists, hematologist-oncologists, hematology-oncology nurse practitioners, emergency physicians, primary care physicians, and other clinicians involved in the management of patients with cold agglutinin disease.

This activity is supported by an independent educational grant from Sanofi Genzyme.

    Presenting Faculty

  • Catherine M. Broome, MD

    Associate Professor of Medicine
    Georgetown University
    MedStar Georgetown University Hospital
    Washington, DC

  • Contributing Faculty

    Alexander Röth, MD

    Department of Hematology and Stem Cell Transplant
    University Hospital Essen
    University of Duisburg-Essen
    Essen, Germany

Learning Objectives

  • Describe the pathogenesis of cold agglutinin disease (CAD), the mechanism of disease, its symptoms, and its possible consequences
  • Diagnose patients suspected of having CAD
  • Appropriately treat and monitor patients with CAD using nonpharmacologic and pharmacologic options
  • Describe the mechanism of action, safety and efficacy of new and emerging treatments for CAD

Faculty Disclosures

Catherine M. Broome, MD

Speakers Bureau: Alexion, Apellis, Argenx, Sanofi


Alexander Röth, MD

Advisor: Alexion, Apellis, BioCryst, Novartis, Roche, Sanofi

Consultant: Alexion, Apellis, BioCryst, Novartis, Roche, Sanofi

Research Support: Roche

Speakers Bureau: Alexion, Novartis Sanofi


Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.00 contact hour, including 0.75 pharmacology hours, may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.00 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Victoria Anderson (Medical Writer)
  • Individual stockholder
    • Abbott 
    • AbbVie

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Heather M. Jimenez, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.